➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Moodys
McKinsey
Johnson and Johnson
Harvard Business School

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

Vicuron Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Vicuron
International Patents:64
US Patents:3
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Vicuron

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 RX Yes Yes 6,960,564   Start Trial Y   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 RX Yes Yes 5,965,525   Start Trial Y Y   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 RX Yes Yes 5,965,525   Start Trial Y Y   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 RX Yes Yes 6,960,564   Start Trial Y   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 RX Yes Yes 7,709,444   Start Trial Y   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 RX Yes Yes 7,709,444   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Vicuron

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 5,965,525   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 5,965,525   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 6,743,777   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 6,743,777   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 6,384,013   Start Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 6,384,013   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Vicuron Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0561639 CA 2008 00017 Denmark   Start Trial
0561639 08C0009 France   Start Trial PRODUCT NAME: ANIDULAFUNGINE; REGISTRATION NO/DATE: EU/1/07/416/001 20070920
0561639 91406 Luxembourg   Start Trial 91406, EXPIRES: 20180318
0561639 SPC/GB08/016 United Kingdom   Start Trial PRODUCT NAME: ANIDULAFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/416/001 20070920
0561639 C300334 Netherlands   Start Trial PRODUCT NAME: ANIDULAFUNGIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/07/416/001 20070920
0561639 SPC002/2008 Ireland   Start Trial SPC002/2008: 20081105, EXPIRES: 20180317
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Merck
McKinsey
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.